| 000 | 01283 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515214345.0 | ||
| 264 | 0 | _c20100610 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1517/14656561003691854 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMathier, Michael A | |
| 245 | 0 | 0 |
_aBosentan. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cApr 2010 |
||
| 300 |
_a1023-34 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadverse effects |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aBosentan |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aEndothelin Receptor Antagonists |
| 650 | 0 | 4 |
_aEndothelins _xmetabolism |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 |
_aExercise Tolerance _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Endothelin _xmetabolism |
| 650 | 0 | 4 |
_aSulfonamides _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aIshizawar, David | |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 11 _gno. 6 _gp. 1023-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14656561003691854 _zAvailable from publisher's website |
| 999 |
_c19670561 _d19670561 |
||